Search results for "Intravenou"

showing 10 items of 390 documents

Nitric oxide mediates the inhibition by interleukin-1β of pentagastrin-stimulated rat gastric acid secretion

1993

Bolus injection of interleukin-1 beta (2 micrograms kg-1, i.v.) inhibited acid secretion induced by intravenous infusion of pentagastrin (8 micrograms kg-1 h-1) in the continuously perfused stomach of the anaesthetized rat. Administration of interleukin-1 beta did not modify mean systemic arterial blood pressure. Pretreatment with NG-nitro-L-arginine methyl ester (L-NAME, 2-10 mg kg-1, i.v.), but not dexamethasone (5 mg kg-1, s.c. twice over 16 h), restored the acid secretory responses to pentagastrin. The actions of L-NAME were reversed by the prior administration of L-arginine (100 mg kg-1, i.v.), but not by its enantiomer D-arginine (100 mg kg-1, i.v.). L-NAME (5 mg kg-1, i.v.) increased…

Malemedicine.medical_specialtyBlood PressureBiologyPeptide hormoneArginineNitric OxideNitric oxideGastric Acidchemistry.chemical_compoundInternal medicinemedicineAnimalsRats WistarInfusions IntravenousPhenylephrineDexamethasonePharmacologyStomachStereoisomerismRatsPentagastrinNG-Nitroarginine Methyl Estermedicine.anatomical_structureEndocrinologychemistryGastrointestinal hormoneGastric acidFemalePentagastrinResearch ArticleInterleukin-1medicine.drugBritish Journal of Pharmacology
researchProduct

The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effect on analgesic response and bone metabolism biomarkers

2005

Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastatic bone disease. We have carried out a perspective study on 24 consecutive patients with prostate cancer metastatic to bone to verify the effect of zoledronic acid on analgesic response and a possible relationship with the levels of bone metabolism biomarkers. Eligibility for this study required prostate cancer patients with metastatic bone disease and pain not controlled by analgesics. Patients were excluded from the study if they were receiving cytotoxic chemotherapy or radiation therapy within three months. Eighteen patients (75%) were considered responder to acid zoledronic, only 6 patient…

Malemedicine.medical_specialtyBone diseasemedicine.medical_treatmentPainBone NeoplasmsGastroenterologyBone resorptionBone remodelingProstate cancerzoledronic acidInternal medicinemedicineHumansPharmacology (medical)Bone ResorptionInfusions Intravenousbone metastaseAgedPain MeasurementPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesProstatic NeoplasmsMiddle AgedBisphosphonatemedicine.diseaseprostate cancerSurgeryRadiation therapyBone Density Conservation AgentsInfectious DiseasesZoledronic acidOncologybone metabolism biomarkerbusinessBiomarkersmedicine.drug
researchProduct

Lethal Anaphylactic Reaction to Intravenous Gelatin in the Course of Surgery

2016

Plasma volume expanders (PVEs) are widely used to increase circulating blood volume. Gelatins used as PVEs are heterogeneous mixtures of polypeptides, usually prepared by hydrolysis of bovine collagen containing large amounts of proline and hydroxyproline residues. It has been shown that gelatins can cause anaphylactic reactions. We describe the case of a 73-year-old man who during surgery for intestinal obstruction presented a lethal anaphylactic reaction after the administration of a PVE containing gelatin lysate. The reaction occurred 10 minutes after the start of plasma expander infusion. Then, patient became comatose, and he died without awakening after 76 days. Necroptic aspects and h…

Malemedicine.medical_specialtyBovine collagenfood.ingredientPlasma SubstitutesBlood volumeAdministration IntravenouPlasma expanderGelatinDrug Hypersensitivity03 medical and health sciencesHydroxyprolinechemistry.chemical_compoundFatal Outcome0302 clinical medicinefoodSettore MED/43 - Medicina LegaleAnaphylaximedicineHumansPharmacology (medical)030212 general & internal medicineComaAdverse effectAnaphylaxisAgedPharmacologyIntravenous Gelatinbusiness.industryPlasma SubstituteAnaphylactic reactionAnaphylactic reactionsGeneral MedicineAdverse reactionPlasma expanderSurgeryLethal Anaphylactic Reaction030228 respiratory systemchemistryPlasma volume expandersAnesthesiaGelatinAdministration IntravenousPlasma volume expanders Lethal Anaphylactic Reaction Intravenous GelatinbusinessIntestinal ObstructionHumanAmerican Journal of Therapeutics
researchProduct

Nitric oxide and prostacyclin lower suprasystemic pulmonary hypertension after cardiopulmonary bypass

1993

In a 3-week-old male newborn persistent suprasystemic pulmonary hypertension developed after surgical valvulotomy for a critical aortic valve stenosis. Because of a residual transvalvular pressure gradient of 35 mmHg and postoperative left as well as right ventricular dysfunction, treatment with inhaled nitric oxide (NO) and intravenously infused prostacyclin (PGI2) was attempted. Low-dose inhaled NO and low dose PGI2 corrected severe pulmonary hypertension and led to an increase in cardiac output. Treatment with NO but not PGI2 was accompanied by a rise in PaO2 and systemic blood pressure. Interruption of NO administration led to a rapid increase in pulmonary arterial pressure to suprasyst…

Malemedicine.medical_specialtyCardiac outputHypertension Pulmonarymedicine.medical_treatmentBlood PressureNitric OxidePostoperative ComplicationsInternal medicineHypoxic pulmonary vasoconstrictionAdministration InhalationmedicineHumansEndothelial dysfunctionInfusions IntravenousPulmonary wedge pressureCardiopulmonary Bypassbusiness.industryHemodynamicsInfant NewbornAortic Valve Stenosismedicine.diseaseEpoprostenolPulmonary hypertensionValvulotomyBlood pressureAnesthesiaAortic valve stenosisPediatrics Perinatology and Child Healthcardiovascular systemCardiologyDrug Therapy CombinationbusinessEuropean Journal of Pediatrics
researchProduct

The influence of Albunex on the pulmonary circulation in patients with pulmonary hypertension or left heart failure.

1996

To determine the safety of the ultrasound contrast agent Albunex, its influence on right and left heart haemodynamics in patients with pulmonary artery hypertension or left heart failure was assessed after intravenous injection. Patients with a left ventricular ejection fraction smaller than 40% or a systolic pulmonary artery pressure greater than 40 mmHg received 0.08 and 0.22 ml.kg -1 Albunex and 10 ml albumin in random order during right heart catheterization and transthoracic echocardiography. Right atrial, systolic and diastolic pulmonary artery and capillary wedge pressures were measured at 3 min and 5 min and cardiac output at 5 min after the intravenous injection of Albunex and cont…

Malemedicine.medical_specialtyCardiac outputPulmonary CirculationHypertension PulmonaryHeart Valve DiseasesContrast MediaBlood PressureCoronary DiseasePulmonary ArteryElectrocardiographyInternal medicinemedicine.arteryAlbuminsmedicineHumansSystoleAtrium (heart)Ejection fractionbusiness.industryCentral venous pressureHemodynamicsMiddle Agedmedicine.diseasePulmonary hypertensionmedicine.anatomical_structureEchocardiographyHeart failurePulmonary arteryInjections IntravenousCardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Novel antihypertensive hexa- and heptapeptides with ACE-inhibiting properties: From the in vitro ACE assay to the spontaneously hypertensive rat

2011

Bioactive ACE inhibiting peptides are gaining interest in hypertension treatment. We have designed and screened six synthetic heptapeptides (PACEI48 to PACEI53) based on two hexapeptide leads (PACEI32 and PACEI34) to improve ACE inhibitory properties and assess their antihypertensive effects. ACE activity was assayed in vitro and ex vivo. Selected peptides were administered to spontaneously hypertensive rats (SHRs) and normotensive Wistar-Kyoto (WKY) rats. In vitro cytotoxicity was assessed with the MTT reduction test. The six heptapeptides at low micromolar concentration produced different degrees of in vitro inhibition of ACE activity using the synthetic substrate HHL or the natural subst…

Malemedicine.medical_specialtyCell SurvivalPhysiologyAdministration OralAngiotensin-Converting Enzyme InhibitorsBlood PressurePeptidyl-Dipeptidase APharmacologyRats Inbred WKYBiochemistryTissue Culture TechniquesMiceCellular and Molecular NeuroscienceEndocrinologySpontaneously hypertensive ratOral administrationRats Inbred SHRInternal medicineRenin–angiotensin systemmedicineAnimalsHumansInfusions IntravenousAntihypertensive AgentsbiologyChemistryAngiotensin-converting enzyme3T3 CellsHep G2 CellsIn vitroRatsCarotid ArteriesEndocrinologyVasoconstrictionHypertensionACE inhibitorbiology.proteinRabbitsAngiotensin Imedicine.symptomOligopeptidesVasoconstrictionEx vivomedicine.drug
researchProduct

Pharmacokinetics and bioavailability of diclofenac in the rat.

1991

Diclofenac sodium is a widely used drug with interesting absorption and disposition features when administered to laboratory animals. The present study was undertaken to assess the pharmacokinetics of the drug after iv and gastrointestinal dosing to rats. Renal excretion of unchanged drug was negligible, but biliary excretion of the drug (unchanged and conjugated) was detected in bile duct-cannulated rats; it accounted for 27.2 and 31.2% of the total dose following iv and intraduodenal administration, respectively. Most of the drug excreted in the bile was conjugated diclofenac; unchanged drug accounted for only 4.7 and 5.4% of total diclofenac excreted in the bile after iv and intraduodena…

Malemedicine.medical_specialtyDiclofenacDuodenumAdministration OralBiological AvailabilityPharmacologyIntestinal absorptionInjectionsDiclofenacPharmacokineticsOral administrationInternal medicinemedicineAnimalsBilePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsEnterohepatic circulationChemistryRats Inbred StrainsDiclofenac SodiumBioavailabilityRatsstomatognathic diseasesmedicine.anatomical_structureEndocrinologyIntestinal AbsorptionData Interpretation StatisticalInjections IntravenousDuodenummedicine.drugJournal of pharmacokinetics and biopharmaceutics
researchProduct

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refr…

2000

Background: Diuretics, have been accepted as first-line treatment in refractory heart failure, but a lack of response is a frequent event. A randomised single blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory NYHA class IV congestive heart failure (CHF). Materials and methods: Sixty patients (21 F/39 M) with refractory CHF (NYHA class IV) of different etiologies, unresponsive to high oral doses of furosemide, ACE-inhibitors, digitalis, and nitrates, aged 65–90 years, were enrolled. They had to have an ejection fraction (EF) < 35%, serum creatinine < 2 mg/dl, B…

Malemedicine.medical_specialtyDiuresisBlood PressurePotassium Chloridechemistry.chemical_compoundBolus (medicine)FurosemideHeart RateHumansMedicineSingle-Blind MethodDiureticsInfusions IntravenousAgedAged 80 and overHeart FailureSaline Solution HypertonicCreatinineEjection fractionbusiness.industryBody WeightSodiumFurosemideMiddle Agedmedicine.diseaseHypokalemiaDiuresisUric AcidSurgerychemistryCreatinineAnesthesiaHeart failurePotassiumDrug Therapy CombinationFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessHyponatremiamedicine.drugEuropean Journal of Heart Failure
researchProduct

The treatment of venous leg ulcers: a new therapeutic use of iloprost

2007

Background: We conducted a study using an intravenous (i.v.) infusion of iloprost in the treatment of venous ulcers to verify whether the association of i.v. iloprost + local therapy + elastic compression has a favorable effect when compared with traditional treatment with local therapy and elastic compression. Study Design: We evaluated the effects of iloprost in 98 consecutive patients with noncomplicated venous ulcers of lower limbs subdivided into 2 groups: the first group (48 patients) received iloprost in saline solution for 3 weeks and the second group (50 patients) received a venous infusion of a saline solution. The patients were examined at baseline time 0 (first visit) and then a…

Malemedicine.medical_specialtyElastic compressionmedicine.medical_treatmentIschemiaPlacebo groupDrug Administration Schedulelaw.inventionRandomized controlled triallawmedicineHumansSingle-Blind MethodIloprostInfusions IntravenousVeinSalineDose-Response Relationship Drugbusiness.industryvenous ulcersiloprostLeg UlcerSignificant differenceMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureDebridementAnesthesiaAnti-Infective Agents LocalFemaleSurgeryVENOUS LEG ULCERS ILOPROSTbusinessPlatelet Aggregation InhibitorsStockings CompressionIloprostmedicine.drug
researchProduct

Fabry disease: enzyme replacement therapy

2003

Fabry disease is a multisystem disorder associated with wide variability in clinical expression. Fabry disease is an X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A. The enzyme defect leads to the systemic accumulation of glycosphingolipids with alpha-galactosyl moieties consisting predominantly of globotriaosylceramide, galabiosylceramide and two additional glycosphingolipids. Four hemizygotes patients with a family history of Fabry disease and deficiency of the enzyme alpha-galactosidase A were selected. Each patient received purified alpha-galactosidase by intravenous infusion (0.2 mg/kg). The infusion was administered every 2 weeks, for 40 min, for a …

Malemedicine.medical_specialtyGlobotriaosylceramideRenal functionVasomotionCorneal dystrophyDermatologyRisk AssessmentGastroenterologyDrug Administration ScheduleSampling Studieschemistry.chemical_compoundInternal medicineHumansMedicineFamily historyInfusions IntravenousDose-Response Relationship Drugbusiness.industryBiopsy NeedleOutcome measuresEnzyme replacement therapymedicine.diseaseImmunohistochemistryFabry diseaseTreatment OutcomeInfectious DiseasesEndocrinologychemistryalpha-GalactosidaseFabry DiseaseFemalebusinessFollow-Up StudiesJournal of the European Academy of Dermatology and Venereology
researchProduct